Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 27, 2009

Koken Inks Deal with Alnylam to Augment RNAi Research Product Offerings

  • Alnylam Pharmaceuticals has granted Koken a nonexclusive, worldwide license to manufacture and provide RNAi research products and services under the Kreutzer-Limmer patent family. This patent family, owned exclusively by Alnylam, covers fundamental aspects of the structure and uses of RNAi products including siRNAs and their use to mediate RNAi in mammalian cells and of RNAi-related mechanisms.

    Koken, based in Japan, will use the patents to manufacture and provide siRNA reagents to industry and academic customers around the world for research purposes.

    “This new agreement continues to underscore the value of the Kreutzer-Limmer patent family as a critical component of fundamental intellectual property in the field of RNAi,” comments Jason Rhodes, vp of business development at Alnylam. “With more than 15 license agreements with global research product suppliers including five in the Asian markets alone, we believe the vast majority of industrial sales of RNAi products for research purposes are currently being made under a license from Alnylam.”

     



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »